Group 1: New Stock Offerings - Tianpu Co., Ltd. (Stock Code: 605255) has a tender offer period from November 20, 2025, to December 19, 2025[1] - Hangzhou Steam Turbine Co., Ltd. (Stock Code: 200771) has a cash option declaration period from November 19, 2025, to November 25, 2025[1] - Central Plaza (Stock Code: 600280) announced on November 20, 2025[1] Group 2: Stock Performance Alerts - Moen Electric (Stock Code: 002451) reported severe abnormal fluctuations on November 14, 2025[1] - ST Yuancheng (Stock Code: 603388) reported severe abnormal fluctuations on November 11, 2025[1] - ST Keli Da (Stock Code: 603828) reported severe abnormal fluctuations on November 12, 2025[1] Group 3: Recent Announcements - Jiumuwang (Stock Code: 601566) announced on November 20, 2025[1] - Taiping Bird (Stock Code: 603877) announced on November 20, 2025[1] - Huaci Co., Ltd. (Stock Code: 001216) announced on November 20, 2025[1]

证券代码：002868 证券简称：*ST 绿康 公告编号：2025-122 绿康生化股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露真实、准确、完整，没有虚假记 载、误导性陈述或者重大遗漏 特别提示： 1、鉴于绿康生化股份有限公司（以下简称"公司"）2024 年经审计期末净 资产为-2,453.61 元，公司股票已被实施"退市风险警示"。此外，公司最近连续 三个会计年度（2022 年、2023 年、2024 年）扣除非经常性损益前后净利润均为 负值，且 2024 年被出具"与持续经营相关的重大不确定性部分"的审计意见， 公司股票被叠加实施"其他风险警示"。 2、公司 2025 年前三季度营业收入为 40,967.34 万元，归属于上市公司股东 的净利润为-8,258.85 万元；归属于上市公司股东的扣除非经常性损益的净利润为 -9,163.06 万元。截至 2025 年 9 月 30 日，公司归属于上市公司股东的所有者权益 为-10,638.20 万元，仍为负数。若公司 2025 年度经审计的期末净资产为负值，根 据《深圳证券交易所股票上市规则》9.3.12 相关规定，公司将被终止上市。 ...

Core Insights - The animal health sector experienced a decline of 0.24% on November 17, with Dayu Biological leading the drop [1] - The Shanghai Composite Index closed at 3972.03, down 0.46%, while the Shenzhen Component Index closed at 13202.0, down 0.11% [1] Stock Performance - Notable gainers included: - Qudongli (code: 920275) with a closing price of 10.68, up 5.12% [1] - *ST Lvkang (code: 002868) with a closing price of 42.57, up 5.01% [1] - Houfeng Holdings (code: 002141) with a closing price of 3.91, up 2.62% [1] - Major decliners included: - Dayu Biological (code: 920970) with a closing price of 8.70, down 3.87% [2] - Ruipu Biological (code: 300119) with a closing price of 20.61, down 2.92% [2] - Zhongmu Co., Ltd. (code: 600195) with a closing price of 7.94, down 1.98% [2] Capital Flow - The animal health sector saw a net outflow of 10.15 million yuan from institutional investors, while retail investors experienced a net outflow of 20.76 million yuan [2] - Conversely, speculative funds recorded a net inflow of 30.91 million yuan [2] Individual Stock Capital Flow - Notable capital flows included: - Biological Shares (code: 600201) with a net inflow of 12.08 million yuan from institutional investors [3] - Xianfeng Holdings (code: 002141) with a net inflow of 9.50 million yuan from institutional investors [3] - Ruipu Biological (code: 300119) with a net inflow of 1.05 million yuan from speculative funds [3] - Decliners in capital flow included: - *ST Lvkang (code: 002868) with a net outflow of 0.79 million yuan from institutional investors [3] - Hai Li Biological (code: 603718) with a net outflow of 2.82 million yuan from institutional investors [3]

Core Viewpoint - *ST Green Health has completed the release of the 100% equity pledge of its wholly-owned subsidiary, Green Health (Yushan) Film Material Co., Ltd., which was previously pledged as collateral for a 160 million yuan acquisition loan [1][2][4] Group 1: Background of the Event - The equity pledge was originally established to secure a 160 million yuan acquisition loan approved by the board on February 21, 2023 [2] - The loan was arranged with China CITIC Bank and was crucial for ensuring the acquisition funding was in place [2] Group 2: Release of Pledge - The company has optimized its collateral structure by replacing the equity pledge with a mortgage on the subsidiary's own assets [3] - Following the completion of the asset mortgage procedures, the company proceeded to release the equity pledge [3] Group 3: Impact of the Event - The release of the equity pledge restores the 100% equity of Green Health (Yushan) to an unencumbered state, enhancing the flexibility for future operations and capital movements [4] - This change reduces the potential risk of the parent company's equity being pledged, thereby strengthening the company's asset structure [4] - The company stated that this release of the equity pledge will not adversely affect its daily operations [4]

证券代码：002868 证券简称：*ST 绿康 公告编号：2025-121 绿康生化股份有限公司 针对上述借款及股权质押事宜，根据公司发展规划需要，上述事项以绿康玉 山自有资产抵押担保的方式向中信银行办理相关手续，绿康玉山自有资产抵押担 保手续办理完成后，公司办理了对绿康玉山100%股权的解除质押手续。详见2025 年 11 月 07 日在《证券日报》和巨潮资讯网（http://www.cninfo.com.cn）披露的 《关于公司向银行申请授信及担保资产调整的公告》（公告编号：2025-115）。 公司于近日收到玉山县市场监督管理局下发的(饶玉)内资股权登记销字 [2025]67659277 号《股权出质注销登记通知书》，公司持有的绿康玉山 100%股 权已全部解除质押。 1 三、备查文件 《股权出质注销登记通知书》 特此公告。 绿康生化股份有限公司 关于公司子公司股权解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、股权质押的基本情况 绿康生化股份有限公司（以下简称"公司"或"绿康生化"）于 2023 年 02 月 21 日召开第四届董事 ...

Core Viewpoint - The animal health sector experienced a slight increase of 0.89% on November 14, with *ST Green Kang leading the gains, while the overall market indices, including the Shanghai Composite Index and Shenzhen Component Index, saw declines of 0.97% and 1.93% respectively [1] Group 1: Market Performance - The closing price of *ST Green Kang was 40.54, reflecting a rise of 5.00% with a trading volume of 204,000 shares and a transaction value of 8.27 million yuan [1] - Other notable performers included Ruipu Biology with a closing price of 21.23, up 1.87%, and Biological Shares at 11.93, up 1.62% [1] - The overall trading volume and transaction values for various companies in the animal health sector were significant, with Biological Shares recording a transaction value of 954 million yuan [1] Group 2: Capital Flow - The animal health sector saw a net outflow of 57.68 million yuan from institutional investors, while retail investors contributed a net inflow of 60.01 million yuan [2] - The capital flow data indicates that *ST Green Kang had a net inflow of 1.42 million yuan from institutional investors, despite a net outflow from retail investors [3] - Other companies like Biological Shares and Ruipu Biology experienced significant net outflows from institutional investors, indicating a shift in investment sentiment [3]

New Stock Issuance - Hai'an Group (Stock Code: 001233) issued at a price of 48.00 on November 14, 2025[1] - Hangzhou Qilun B (Stock Code: 200771) has a cash option declaration period from November 19 to November 25, 2025[1] - Hailianxun (Stock Code: 300277) has a buyback request declaration period from November 12 to November 18, 2025[1] Market Alerts - Pingming Technology (Stock Code: 688109) reported severe abnormal fluctuations on November 13, 2025[1] - ST Yuancheng (Stock Code: 603388) and ST Zhongzhu (Stock Code: 600568) also reported abnormal fluctuations on November 11, 2025[1] - ST Green Kang (Stock Code: 002868) and Dongbai Group (Stock Code: 600693) reported abnormal fluctuations on November 14, 2025[1] Additional Information - Multiple companies including ST Meigu (Stock Code: 000615) and ST Xiangyu (Stock Code: 600107) have ongoing announcements related to stock performance and market conditions[1][2] - The report includes links to detailed announcements for each stock, providing transparency and access to further information for investors[1]

Group 1 - The Fujian sector demonstrated resilience and outperformed the market with an average increase of 1.83%, despite a general decline in major A-share indices [1] - A total of 14 stocks in the Fujian sector hit the daily limit up, including notable performers such as Sanmu Group with six consecutive limit ups and *ST Lvkang with seven consecutive limit ups, indicating strong market sentiment towards local stocks [1][2] - The Fujian provincial government has introduced multiple policies since November 2025 to support artificial intelligence, computing infrastructure, new energy, cross-strait integration, and cultural tourism consumption, which has attracted capital attention to the Fujian sector [1][3] Group 2 - Fujian's lithium battery exports reached a record high of 108.38 billion yuan from January to October, accounting for 11.3% of the province's total exports, driven by the global demand for green low-carbon products [3] - The ongoing cross-strait integration policies and Fujian's strategic position as a core area of the "21st Century Maritime Silk Road" are expected to benefit infrastructure, port logistics, and real estate sectors in the long term [2][3] - The development of the marine economy and the focus on high-end marine equipment and engineering are anticipated to further enhance Fujian's economic growth, with companies like Zhongmin Energy leveraging local wind energy resources for stable development [3]

二、被提名人不存在《中华人民共和国公司法》第一 百七十八条等规定不得担任公司董事的情形。 提名人绿康生化股份有限公司董事会现就提名蔡文武 为绿康生化股份有限公司第 五届董事会独立董事候选人发 表公开声明。被提名人已书面同意作为绿康生化股份有限 公司第五 届董事会独立董事候选人（参见该独立董事候 选人声明）。本次提名是在充分了解被提名人职业、学历 、职称、详细的工作经历、全部兼职、有无重大失信等不 良记录等情况后作出的，本提名人认为被提名人符合相关 法律、行政法规、部门规章、规范性文件和深圳证券交易 所业务规则对独立董事候选人任职资格及独立性的要求， 具体声明并承诺如下事项： 一、被提名人已经通过绿康生化股份有限公司第五 届董事会提名委员会或者独立董事专门会议资格审查，提 名人与被提名人不存在利害关系或者其他可能影响独立履 职情形的密切关系。 ☑ 是 □ 否 如否，请详细说明：_______________________________ 绿康生化股份有限公司 独立董事提名人声明与承诺 ☑ 是 □ 否 如否，请详细说明：_______________________________ 三、被提名人符合中国证监会《 ...

一、本人已经通过绿康生化股份有限公司第五届董事 会提名委员会或者独立董事专门会议资格审查，提名人与 本人不存在利害关系或者其他可能影响独立履职情形的密 切关系。 ☑ 是 □ 否 如否，请详细说明：_______________________________ 绿康生化股份有限公司 独立董事候选人声明与承诺 声明人蔡文武作为绿康生化股份有限公司第五届董事 会独立董事候选人，已充分了解并同意由提名人绿康生化 股份有限公司董事会提名为绿康生化股份有限公司（以下 简称该公司）第五届董事会独立董事候选人。现公开声明 和保证，本人与该公司之间不存在任何影响本人独立性的 关系，且符合相关法律、行政法规、部门规章、规范性文 件和深圳证券交易所业务规则对独立董事候选人任职资格 及独立性的要求，具体声明并承诺如下事项： 二、本人不存在《中华人民共和国公司法》第一百七 十八条等规定不得担任公司董事的情形。 ☑ 是 □ 否 如否，请详细说明：_______________________________ 三、本人符合中国证监会《上市公司独立董事管理办 法》和深圳证券交易所业务规则规定的独立董事任职资格 和条件。 ☑ 是 □ 否 如否 ...